214 related articles for article (PubMed ID: 22451500)
1. Predominance of pathogenic missense variants in the RAD51C gene occurring in breast and ovarian cancer families.
Osorio A; Endt D; Fernández F; Eirich K; de la Hoya M; Schmutzler R; Caldés T; Meindl A; Schindler D; Benitez J
Hum Mol Genet; 2012 Jul; 21(13):2889-98. PubMed ID: 22451500
[TBL] [Abstract][Full Text] [Related]
2. Analysis of RAD51C germline mutations in high-risk breast and ovarian cancer families and ovarian cancer patients.
Thompson ER; Boyle SE; Johnson J; Ryland GL; Sawyer S; Choong DY; kConFab ; Chenevix-Trench G; Trainer AH; Lindeman GJ; Mitchell G; James PA; Campbell IG
Hum Mutat; 2012 Jan; 33(1):95-9. PubMed ID: 21990120
[TBL] [Abstract][Full Text] [Related]
3. Screening RAD51C nucleotide alterations in patients with a family history of breast and ovarian cancer.
Zheng Y; Zhang J; Hope K; Niu Q; Huo D; Olopade OI
Breast Cancer Res Treat; 2010 Dec; 124(3):857-61. PubMed ID: 20697805
[TBL] [Abstract][Full Text] [Related]
4. Further evidence for the contribution of the RAD51C gene in hereditary breast and ovarian cancer susceptibility.
Vuorela M; Pylkäs K; Hartikainen JM; Sundfeldt K; Lindblom A; von Wachenfeldt Wäppling A; Haanpää M; Puistola U; Rosengren A; Anttila M; Kosma VM; Mannermaa A; Winqvist R
Breast Cancer Res Treat; 2011 Dec; 130(3):1003-10. PubMed ID: 21750962
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of RAD51C as cancer susceptibility gene in a large breast-ovarian cancer patient population referred for genetic testing.
De Leeneer K; Van Bockstal M; De Brouwer S; Swietek N; Schietecatte P; Sabbaghian N; Van den Ende J; Willocx S; Storm K; Blaumeiser B; Van Asperen CJ; Wijnen JT; Leunen K; Legius E; Michils G; Matthijs G; Blok MJ; Gomez-Garcia E; De Paepe A; Tischkowitz M; Poppe B; Claes K
Breast Cancer Res Treat; 2012 May; 133(1):393-8. PubMed ID: 22370629
[TBL] [Abstract][Full Text] [Related]
6. Identification of six pathogenic RAD51C mutations via mutational screening of 1228 Danish individuals with increased risk of hereditary breast and/or ovarian cancer.
Jønson L; Ahlborn LB; Steffensen AY; Djursby M; Ejlertsen B; Timshel S; Nielsen FC; Gerdes AM; Hansen TV
Breast Cancer Res Treat; 2016 Jan; 155(2):215-22. PubMed ID: 26740214
[TBL] [Abstract][Full Text] [Related]
7. RAD51C germline mutations found in Spanish site-specific breast cancer and breast-ovarian cancer families.
Blanco A; Gutiérrez-Enríquez S; Santamariña M; Montalban G; Bonache S; Balmaña J; Carracedo A; Diez O; Vega A
Breast Cancer Res Treat; 2014 Aug; 147(1):133-43. PubMed ID: 25086635
[TBL] [Abstract][Full Text] [Related]
8. Deleterious RAD51C germline mutations rarely predispose to breast and ovarian cancer in Pakistan.
Rashid MU; Muhammad N; Faisal S; Amin A; Hamann U
Breast Cancer Res Treat; 2014 Jun; 145(3):775-84. PubMed ID: 24800917
[TBL] [Abstract][Full Text] [Related]
9. RAD51C is a susceptibility gene for ovarian cancer.
Pelttari LM; Heikkinen T; Thompson D; Kallioniemi A; Schleutker J; Holli K; Blomqvist C; Aittomäki K; Bützow R; Nevanlinna H
Hum Mol Genet; 2011 Aug; 20(16):3278-88. PubMed ID: 21616938
[TBL] [Abstract][Full Text] [Related]
10. RAD51C mutation screening in high-risk patients from Serbian hereditary breast/ovarian cancer families.
Krivokuca A; Yanowski K; Rakobradovic J; Benitez J; Brankovic-Magic M
Cancer Biomark; 2015; 15(6):775-81. PubMed ID: 26406419
[TBL] [Abstract][Full Text] [Related]
11. BRIP1, PALB2, and RAD51C mutation analysis reveals their relative importance as genetic susceptibility factors for breast cancer.
Wong MW; Nordfors C; Mossman D; Pecenpetelovska G; Avery-Kiejda KA; Talseth-Palmer B; Bowden NA; Scott RJ
Breast Cancer Res Treat; 2011 Jun; 127(3):853-9. PubMed ID: 21409391
[TBL] [Abstract][Full Text] [Related]
12. Genetic testing for RAD51C mutations: in the clinic and community.
Sopik V; Akbari MR; Narod SA
Clin Genet; 2015 Oct; 88(4):303-12. PubMed ID: 25470109
[TBL] [Abstract][Full Text] [Related]
13. Mutational analysis of the BRCA1-interacting genes ZNF350/ZBRK1 and BRIP1/BACH1 among BRCA1 and BRCA2-negative probands from breast-ovarian cancer families and among early-onset breast cancer cases and reference individuals.
Rutter JL; Smith AM; Dávila MR; Sigurdson AJ; Giusti RM; Pineda MA; Doody MM; Tucker MA; Greene MH; Zhang J; Struewing JP
Hum Mutat; 2003 Aug; 22(2):121-8. PubMed ID: 12872252
[TBL] [Abstract][Full Text] [Related]
14. Novel BRCA1 and BRCA2 germline mutations and assessment of mutation spectrum and prevalence in Italian breast and/or ovarian cancer families.
Giannini G; Capalbo C; Ristori E; Ricevuto E; Sidoni T; Buffone A; Cortesi E; Marchetti P; Scambia G; Tomao S; Rinaldi C; Zani M; Ferraro S; Frati L; Screpanti I; Gulino A
Breast Cancer Res Treat; 2006 Nov; 100(1):83-91. PubMed ID: 16847550
[TBL] [Abstract][Full Text] [Related]
15. Mutation analysis and characterization of ATR sequence variants in breast cancer cases from high-risk French Canadian breast/ovarian cancer families.
Durocher F; Labrie Y; Soucy P; Sinilnikova O; Labuda D; Bessette P; Chiquette J; Laframboise R; Lépine J; Lespérance B; Ouellette G; Pichette R; Plante M; Tavtigian SV; Simard J
BMC Cancer; 2006 Sep; 6():230. PubMed ID: 17010193
[TBL] [Abstract][Full Text] [Related]
16. Characterisation of the novel deleterious RAD51C p.Arg312Trp variant and prioritisation criteria for functional analysis of RAD51C missense changes.
Gayarre J; Martín-Gimeno P; Osorio A; Paumard B; Barroso A; Fernández V; de la Hoya M; Rojo A; Caldés T; Palacios J; Urioste M; Benítez J; García MJ
Br J Cancer; 2017 Sep; 117(7):1048-1062. PubMed ID: 28829762
[TBL] [Abstract][Full Text] [Related]
17. Analysis of FANCB and FANCN/PALB2 fanconi anemia genes in BRCA1/2-negative Spanish breast cancer families.
García MJ; Fernández V; Osorio A; Barroso A; Llort G; Lázaro C; Blanco I; Caldés T; de la Hoya M; Ramón Y Cajal T; Alonso C; Tejada MI; San Román C; Robles-Díaz L; Urioste M; Benítez J
Breast Cancer Res Treat; 2009 Feb; 113(3):545-51. PubMed ID: 18302019
[TBL] [Abstract][Full Text] [Related]
18. Mutation screening of RAD51C in high-risk breast and ovarian cancer families.
Lu W; Wang X; Lin H; Lindor NM; Couch FJ
Fam Cancer; 2012 Sep; 11(3):381-5. PubMed ID: 22476429
[TBL] [Abstract][Full Text] [Related]
19. BRCA1 genetic testing in 106 breast and ovarian cancer families from Southern Italy (Sicily): a mutation analyses.
Russo A; Calò V; Agnese V; Bruno L; Corsale S; Augello C; Gargano G; Barbera F; Cascio S; Intrivici C; Rinaldi G; Gulotta G; Macaluso M; Surmacz E; Giordano A; Gebbia N; Bazan V
Breast Cancer Res Treat; 2007 Nov; 105(3):267-76. PubMed ID: 17221156
[TBL] [Abstract][Full Text] [Related]
20. Contributions of ATM mutations to familial breast and ovarian cancer.
Thorstenson YR; Roxas A; Kroiss R; Jenkins MA; Yu KM; Bachrich T; Muhr D; Wayne TL; Chu G; Davis RW; Wagner TM; Oefner PJ
Cancer Res; 2003 Jun; 63(12):3325-33. PubMed ID: 12810666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]